References
- American Diabetes Association. Nephropathy in diabetes. Diabetes Care. 2004; 27(Suppl 1): S79–S83.
- Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777–1782.
- De Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol. 2006; 17: 2120–2126.
- HemoCue® AB, Ängelholm, Sweden. HemoCue® Albumin 201 system with HemoCue® microcuvettes. Package insert, 2004.
- Bayer Healthcare LLC, Elkhart, Ind USA. Clinitek® microalbumin reagent strips for determining albumin and creatinine in urine. Package insert, 2006.
- Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002; 48(3): 436–472.
- Florvall G, Helmersson J, Basu S, Larsson A. HemoCue® urine albumin point-of-care test shows strong agreement with the results obtained with a large nephelometer. Diabetes Care. 2006; 6(2): 422–423.
- Sarafadis PA, Riehle J, Bogojevic Z, Basta E, et al. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28: 324–349.
- Le Floch JP, Marre M, Rodier M, Passa PH. Interest of Clinitek® microalbumin in screening for microalbuminuria: results of a multicentre study in 302 diabetic patients. Diabetes Metab. 2001; 27: 36–39.
- Wilde HM, Banks D, Larsen CL, et al. Evaluation of the Bayer microalbumin/creatinine urinalysis dipstick. Clinica Chimica Acta. 2008; 393: 110–113.